<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pak J Med Sci</journal-id><journal-id journal-id-type="iso-abbrev">Pak J Med Sci</journal-id><journal-id journal-id-type="publisher-id">PJMS</journal-id><journal-title-group><journal-title>Pakistan Journal of Medical Sciences</journal-title></journal-title-group><issn pub-type="ppub">1682-024X</issn><issn pub-type="epub">1681-715X</issn><publisher><publisher-name>Professional Medical Publications</publisher-name><publisher-loc>Pakistan</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26101481</article-id><article-id pub-id-type="pmc">4476332</article-id><article-id pub-id-type="publisher-id">PJMS-31-309</article-id><article-id pub-id-type="doi">10.12669/pjms.312.6536</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>A comparison study on the clinical effects of foscarnet sodium injection and interferon on human immunodeficiency virus-infected patients complicated with herpes zoster</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yuan-Qu</surname><given-names>Yuan</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Xiong-Pu</surname><given-names>Ming</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Xiao-Kang</surname><given-names>Jing</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Cai-An</surname><given-names>Xia</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Yuan-Yuan Qu, Department of Dermatology and Venereology, Anhui Medical University, Hefei, Anhui Province, China</aff><aff id="aff2"><label>2</label>Xiong-Ming Pu, Department of Dermatology, People&#x02019;s Hospital of Xinjiang, Urumqi, Xinjiang Uygur Autonomous Region, China</aff><aff id="aff3"><label>3</label>Xiao-Jing Kang, Department of Dermatology, People&#x02019;s Hospital of Xinjiang, Urumqi, Xinjiang Uygur Autonomous Region, China</aff><aff id="aff4"><label>4</label>Cai-Xia An, Department of Dermatology, People&#x02019;s Hospital of Xinjiang, Urumqi, Xinjiang Uygur Autonomous Region, China</aff><author-notes><corresp id="cor1">
Correspondence: Prof. Xiong-ming Pu, E-mail: <email xlink:href="puxiongmingdd@163.com">puxiongmingdd@163.com</email><email xlink:href="puxiongming@126.com">puxiongming@126.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Mar-Apr</season><year>2015</year></pub-date><volume>31</volume><issue>2</issue><fpage>309</fpage><lpage>313</lpage><history><date date-type="received"><day>30</day><month>9</month><year>2014</year></date><date date-type="rev-recd"><day>18</day><month>12</month><year>2014</year></date><date date-type="accepted"><day>05</day><month>1</month><year>2015</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Pakistan Journal of Medical Sciences</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0"><license-p><!--CREATIVE COMMONS-->This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0">http://creativecommons.org/licenses/by/3.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title>Objective:</title><p>To compare the clinical effects of foscarnet sodium injection and interferon on human immunodeficiency virus (HIV)-infected patients complicated with herpes zoster.</p></sec><sec id="st2"><title>Methods:</title><p>Ninety HIV-infected patients complicated with herpes zoster were divided into a treatment group and a control group that were both treated routinely first. Then the control group and treatment group were administered with interferon and foscarnet sodium injection respectively for four consecutive weeks.</p></sec><sec id="st3"><title>Results:</title><p>After four weeks, the effective rates of the treatment and control groups were 95.6% and 80.0% respectively, which were significantly different (P &#x0003c; 0.05). The pain scores of the two groups were similar before treatment, but the scores of the treatment group were significantly lower than those of the control group two and four weeks after treatment (P &#x0003c; 0.05) as well as were significantly lower than those before treatment (P &#x0003c; 0.05). The numbers of CD4+ cells and the contents of IL-2 of both groups two and four weeks after treatment significantly exceeded those before treatment (P &#x0003c; 0.05), with significant inter-group differences also (P &#x0003c; 0.05). Two and four weeks after treatment, the treatment group scored significantly higher in physical activity, energy, sleep, social life and emotional reaction than the control group did (P &#x0003c; 0.05).</p></sec><sec id="st4"><title>Conclusions:</title><p>HIV-infected patients are prone to being complicated with herpes zoster. Compared with interferon, foscarnet sodium injection better improves the clinical outcomes by effectively relieving pain and by regulating immune mediated inflammatory diseases, thus boosting the prognostic quality of life.</p></sec></abstract><kwd-group><title>KEY WORDS</title><kwd>HIV infection</kwd><kwd>Herpes zoster</kwd><kwd>Foscarnet sodium</kwd><kwd>Interferon</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>INTRODUCTION</title><p>Currently, human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) have been severely endangering the whole world as public health issues.<xref rid="ref1" ref-type="bibr">1</xref>,<xref rid="ref2" ref-type="bibr">2</xref> Epidemiological studies have shown that of about seven hundred thousand HIV-infected patients, approximately one hundred thousand ones suffered from AIDS that was mainly transmitted sexually or by intravenous drug injection.<xref rid="ref3" ref-type="bibr">3</xref>-<xref rid="ref5" ref-type="bibr">5</xref> Herpes zoster, as an acute infectious skin disease induced by Varicella-Zoster virus (VZV), is typified by distribution of rash along peripheral nerve segments and neuralgia. During early infection, the virus lurks in the dorsal root neurons persistently, which, upon cellular immune dysfunction, is activated to induce ganglion inflammation, necrosis and acute skin damages.<xref rid="ref6" ref-type="bibr">6</xref></p><p>The patients with herpes zoster undergo long-term pain, depression and decrease in quality of life. There remain no eligible drugs for treating HIV plus herpes zoster, which are thus now routinely treated by anti-inflammation, infection prevention, disease course shortening and symptom-targeting strategies with antiviral agents, interferon, corticoids, transfer factors and B vitamins, etc.<xref rid="ref7" ref-type="bibr">7</xref> Interferon can inhibit virus from damaging nerves, control acute-phase symptoms and prevent postherpetic neuralgia, but it may lead to adverse reactions and high recurrence rates.<xref rid="ref8" ref-type="bibr">8</xref></p><p>With wide application of highly active anti-retroviral therapy in AIDS patients, anti-HIV treatment has obtained triumphs, and the transmission of HIV has been well controlled. However, resistant viruses have increased due to long-term individual use of a certain drug.<xref rid="ref9" ref-type="bibr">9</xref> Foscarnet sodium injection is a well-known, broad-spectrum antiviral agent. By directly binding to the pyrophosphate binding sites of RNA and DNA polymerases, foscarnet, as a non-nucleoside analog of pyrophosphate, non-competitively inhibits enzyme activity with nucleotide substrates.<xref rid="ref10" ref-type="bibr">10</xref> Besides, it selectively suppresses virus-specific DNA polymerase and well inhibits hepatitis B virus replication.<xref rid="ref11" ref-type="bibr">11</xref></p><p>In this study, we compared the clinical effects of foscarnet sodium injection and interferon on HIV-infected patients complicated with herpes zoster.</p></sec><sec sec-type="methods" id="sec1-2"><title>METHODS</title><sec id="sec2-1"><title>Subjects</title><p>Ninety HIV-infected patients complicated with herpes zoster who were treated in our hospital from February 2008 to December 2013 were selected in this study.</p></sec><sec id="sec2-2"><title>Inclusion Criteria</title><p>In accordance with &#x0201c;Diagnostic criteria and principles of management of asymptomatic HIV/AIDS&#x0201d; (P. R. China, 2001 edition); expected survival rime &#x0003e; 1 year; with herpes and severe neuropathic pain within 1-7 days, without receiving antiviral or analgesic therapy; with written consent form to accept all possible therapies; 18-65 years old.</p></sec><sec id="sec2-3"><title>Exclusion standards</title><p>Severe liver and renal insufficiencies, or those complicated with severe primary cardiovascular, lung and hematopoietic system diseases; psychiatric patients; pregnant or lactating women; allergic to the drugs used herein; with primary immunodeficiency, hormone- or chemotherapy-induced secondary immunodeficiencies, or hematological diseases. Platelet count &#x0003c; 60&#x000d7;10<sup>9</sup>/L. The patients were divided into a treatment group and a control group by random draw (n=45), and their gender, age, disease course, education time, body mass index and history of drug injection were similar (P &#x0003e; 0.05) (<xref ref-type="table" rid="T1">Table-I</xref>).</p><table-wrap id="T1" position="float"><label>Table-I</label><caption><p>Baseline clinical data.</p></caption><table frame="hsides" rules="rows" width="100%"><colgroup span="1"><col align="left" valign="top" width="0%" span="1"/><col align="char" char="." valign="top" width="15%" span="1"/><col align="char" char="." valign="top" width="15%" span="1"/><col align="char" char="." valign="top" width="15%" span="1"/><col align="char" char="." valign="top" width="15%" span="1"/><col align="char" char="." valign="top" width="15%" span="1"/><col align="char" char="." valign="top" width="15%" span="1"/><col align="char" char="." valign="top" width="10%" span="1"/></colgroup><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Group</th><th valign="top" align="left" rowspan="1" colspan="1">Gender (male/female)</th><th valign="top" align="left" rowspan="1" colspan="1">History of drug injection (case)</th><th valign="top" align="left" rowspan="1" colspan="1">Age (years old)</th><th valign="top" align="left" rowspan="1" colspan="1">Disease course (year)</th><th valign="top" align="left" rowspan="1" colspan="1">Education time (year)</th><th valign="top" align="left" rowspan="1" colspan="1">Body mass index (kg/m<sup>2</sup>)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Treatment group (n=45)</td><td align="left" rowspan="1" colspan="1">25/20</td><td align="left" rowspan="1" colspan="1">21(46.7%)</td><td align="left" rowspan="1" colspan="1">46.44&#x000b1;2.87</td><td align="left" rowspan="1" colspan="1">4.22&#x000b1;0.45</td><td align="left" rowspan="1" colspan="1">12.73&#x000b1;6.13</td><td align="left" rowspan="1" colspan="1">19.78&#x000b1;5.22</td></tr><tr><td align="left" rowspan="1" colspan="1">Control group (n=45)</td><td align="left" rowspan="1" colspan="1">24/21</td><td align="left" rowspan="1" colspan="1">20(44.4%)</td><td align="left" rowspan="1" colspan="1">46.39&#x000b1;3.13</td><td align="left" rowspan="1" colspan="1">4.23&#x000b1;0.65</td><td align="left" rowspan="1" colspan="1">12.77&#x000b1;5.33</td><td align="left" rowspan="1" colspan="1">19.36&#x000b1;5.33</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x003c7;<sup>2</sup></td><td align="left" rowspan="1" colspan="1">0.078</td><td align="left" rowspan="1" colspan="1">0.50</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">t</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.065</td><td align="left" rowspan="1" colspan="1">0.009</td><td align="left" rowspan="1" colspan="1">0.067</td><td align="left" rowspan="1" colspan="1">0.302</td></tr><tr><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.05</td></tr></tbody></table></table-wrap></sec><sec id="sec2-4"><title>Treatment methods</title></sec><sec id="sec2-5"><title>Basic treatment</title><p>1.2 g reduced glutathione; 150 mg diammonium glycyrrhizinate, qd, intravenous infusion; oral administration of valacyclovir hydrochloride, 300 mg per time, bid; oral administration of vitamin B1, 10 mg, tid.</p></sec><sec id="sec2-6"><title>Control group</title><p>Based on the basic treatment, 50 million U IFN &#x003b1;-2b interferon (Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd.) was intramuscular injected, qd.</p></sec><sec id="sec2-7"><title>Treatment group</title><p>Based on the basic treatment, 3.0 g foscarnet sodium injection (Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd.) was intravenously infused, bid. Both groups were treated for four consecutive weeks, with seven days as a course of treatment. Serum and proteins were used to support treatment, but immunomodulators, jaundice-removing agents, other antiviral drugs or plasmapheresis were not employed.</p></sec><sec id="sec2-8"><title>Observation indices</title><p>Determination of therapeutic effects: Evaluation was performed four weeks after treatment. Markedly effective: Disappearance of rash and clinical signs (Rash means skin changes such as color, appearance, or texture; clinical signs mean pain, depression and decrease in quality of life), and significantly mitigated pain and itching; effective: disappearance of 30% rash, significantly decreased clinical signs, and mitigated pain and itching; ineffective: unable to reach the above standards.</p></sec><sec id="sec2-9"><title>Pain rating</title><p>Degree of pain was rated before as well as two and four weeks after treatment by visual analogous scale, with 0 being painless and 100 being the maximum pain that patients could imagine. The scale was completed by patients.</p></sec><sec id="sec2-10"><title>Investigation on quality of life</title><p>Nottingham health profile, which includes physical activity, energy, sleep, social life and emotional reaction, was used to investigate the patients two and four weeks after treatment. From 0 to 100, a higher score means better quality of life. The profile was highly reliable and valid.</p></sec><sec id="sec2-11"><title>Comparisons of inflammatory and immune cytokines</title><p>Before as well as two and four weeks after treatment, 5 mL of venous blood was collected and stored in a -20&#x000b0;C refrigerator after separating serum at low temperature. Interleukin-2 (IL-2) content was detected by polyclonal antibody-based sandwich ELISA according to the instructions of kit (Genzyme, USA). CD4+ cells were counted according to instructions by experienced personnel in our hospital.</p></sec><sec id="sec2-12"><title>Statistical analysis</title><p>All data were analyzed by SPSS 17.0. The categorical data were expressed as (x &#x000b1; s), and intra-group and inter-group comparisons were performed by using t test and independent analysis of variance. The numerical data were compared by Chi-square analysis. P &#x0003c; 0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results" id="sec1-3"><title>RESULTS</title><sec id="sec2-13"><title>Clinical effects</title><p>Four weeks after treatment, the effective rate of the treatment group (95.6%) was significantly higher than that of the control group (80.0%) (P &#x0003c; 0.05) (<xref ref-type="table" rid="T2">Table-II</xref>).</p><table-wrap id="T2" position="float"><label>Table-II</label><caption><p>Clinical effects (n).</p></caption><table frame="hsides" rules="rows" width="100%"><colgroup span="1"><col align="left" valign="top" width="0%" span="1"/><col align="char" char="." valign="top" width="20%" span="1"/><col align="char" char="." valign="top" width="10%" span="1"/><col align="char" char="." valign="top" width="20%" span="1"/><col align="char" char="." valign="top" width="20%" span="1"/><col align="char" char="." valign="top" width="15%" span="1"/><col align="char" char="." valign="top" width="15%" span="1"/></colgroup><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Group</th><th valign="top" align="center" rowspan="1" colspan="1">Case No.</th><th valign="top" align="center" rowspan="1" colspan="1">Markedly effective</th><th valign="top" align="center" rowspan="1" colspan="1">Effective</th><th valign="top" align="center" rowspan="1" colspan="1">Ineffective</th><th valign="top" align="center" rowspan="1" colspan="1">Overall effective rate</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Treatment group</td><td align="center" rowspan="1" colspan="1">45</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">95.6%</td></tr><tr><td align="left" rowspan="1" colspan="1">Control group</td><td align="center" rowspan="1" colspan="1">45</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">80.0%</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x003c7;&#x000b2; </td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">7.193</td></tr><tr><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x0003c;0.05</td></tr></tbody></table></table-wrap></sec><sec id="sec2-14"><title>Pain scores</title><p>The pain scores of the two groups were similar before treatment, but the scores of the treatment group were significantly lower than those of the control group two and four weeks after treatment (P &#x0003c; 0.05) as well as were significantly lower than those before treatment (P &#x0003c; 0.05) (<xref ref-type="table" rid="T3">Table-III</xref>).</p><table-wrap id="T3" position="float"><label>Table-III</label><caption><p>Pain scores at different time points before and after treatment (point, x &#x000b1; s).</p></caption><table frame="hsides" rules="rows" width="100%"><colgroup span="1"><col align="left" valign="top" width="0" span="1"/><col align="char" char="." valign="top" width="15%" span="1"/><col align="char" char="." valign="top" width="25%" span="1"/><col align="char" char="." valign="top" width="20%" span="1"/><col align="char" char="." valign="top" width="20%" span="1"/><col align="char" char="." valign="top" width="20%" span="1"/></colgroup><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Group</th><th valign="top" align="center" rowspan="1" colspan="1">Case No. (n)</th><th valign="top" align="left" rowspan="1" colspan="1">Before</th><th valign="top" align="center" rowspan="1" colspan="1">Two weeks after</th><th valign="top" align="center" rowspan="1" colspan="1">Four weeks after</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Treatment group</td><td align="center" rowspan="1" colspan="1">45</td><td align="left" rowspan="1" colspan="1">80.44&#x000b1;7.13</td><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;12.87&#x000b1;5.33</td><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;6.89&#x000b1;3.12</td></tr><tr><td align="left" rowspan="1" colspan="1">Control group</td><td align="center" rowspan="1" colspan="1">45</td><td align="left" rowspan="1" colspan="1">80.65&#x000b1;6.09</td><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;34.17&#x000b1;5.11</td><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;20.11&#x000b1;4.01</td></tr><tr><td align="left" rowspan="1" colspan="1">t</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.028</td><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;22.863</td><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;14.992</td></tr><tr><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x0003c;0.05</td><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x0003c;0.05</td></tr></tbody></table></table-wrap></sec><sec id="sec2-15"><title>Changes of inflammatory and immune cytokines</title><p>The numbers of CD4+ cells and the contents of IL-2 of both groups two and four weeks after treatment significantly exceeded those before treatment (P &#x0003c; 0.05), with significant inter-group differences also (P &#x0003c; 0.05) (<xref ref-type="table" rid="T4">Table-IV</xref>).</p><table-wrap id="T4" position="float"><label>Table-IV</label><caption><p>Numbers of CD4+ cells and IL-2 contents at different time points before and after treatment (x &#x000b1; s).</p></caption><table frame="hsides" rules="rows" width="100%"><colgroup span="1"><col align="left" valign="top" width="0%" span="1"/><col align="char" char="." valign="top" width="15%" span="1"/><col align="char" char="." valign="top" width="10%" span="1"/><col align="char" char="." valign="top" width="10%" span="1"/><col align="char" char="." valign="top" width="13%" span="1"/><col align="char" char="." valign="top" width="13%" span="1"/><col align="char" char="." valign="top" width="13%" span="1"/><col align="char" char="." valign="top" width="13%" span="1"/><col align="char" char="." valign="top" width="13%" span="1"/></colgroup><thead><tr><th align="left" valign="top" rowspan="2" colspan="1">Group</th><th align="center" valign="top" rowspan="2" colspan="1">Case No. (n)</th><th align="center" valign="top" colspan="3" rowspan="1">Number of CD4+ cells (count/&#x003bc;l)</th><th align="center" valign="top" colspan="3" rowspan="1">IL-2 content (ng/L)</th></tr><tr><th align="left" valign="top" rowspan="1" colspan="1">Before</th><th align="left" valign="top" rowspan="1" colspan="1">Two weeks after</th><th align="left" valign="top" rowspan="1" colspan="1">Four weeks after</th><th align="left" valign="top" rowspan="1" colspan="1">Before</th><th align="left" valign="top" rowspan="1" colspan="1">Two weeks after</th><th align="left" valign="top" rowspan="1" colspan="1">Four weeks after</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Treatment group</td><td align="center" rowspan="1" colspan="1">45</td><td align="left" rowspan="1" colspan="1">109.37&#x000b1;45.33</td><td align="left" rowspan="1" colspan="1">302.76&#x000b1;60.27</td><td align="left" rowspan="1" colspan="1">338.65&#x000b1;59.09</td><td align="left" rowspan="1" colspan="1">445.22&#x000b1;90.37</td><td align="left" rowspan="1" colspan="1">879.68&#x000b1;78.03</td><td align="left" rowspan="1" colspan="1">1165.98&#x000b1;109.33</td></tr><tr><td align="left" rowspan="1" colspan="1">Control group</td><td align="center" rowspan="1" colspan="1">45</td><td align="left" rowspan="1" colspan="1">111.76&#x000b1;46.01</td><td align="left" rowspan="1" colspan="1">198.26&#x000b1;45.11</td><td align="left" rowspan="1" colspan="1">230.68&#x000b1;63.45</td><td align="left" rowspan="1" colspan="1">448.26&#x000b1;43.09</td><td align="left" rowspan="1" colspan="1">600.38&#x000b1;61.34</td><td align="left" rowspan="1" colspan="1">876.63&#x000b1;78.26</td></tr><tr><td align="left" rowspan="1" colspan="1">t</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.284</td><td align="left" rowspan="1" colspan="1">17.367</td><td align="left" rowspan="1" colspan="1">9.367</td><td align="left" rowspan="1" colspan="1">0.391</td><td align="left" rowspan="1" colspan="1">34.762</td><td align="left" rowspan="1" colspan="1">21.093</td></tr><tr><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.05</td></tr></tbody></table></table-wrap></sec><sec id="sec2-16"><title>Evaluation on quality of life</title><p>Two and four weeks after treatment, the treatment group scored significantly higher in physical activity, energy, sleep, social life and emotional reaction than the control group did (P &#x0003c; 0.05) (<xref ref-type="table" rid="T5">Table-V</xref>).</p><table-wrap id="T5" position="float"><label>Table-V</label><caption><p>Scores in quality of life at different time points before and after treatment (point, x &#x000b1; s).</p></caption><table frame="hsides" rules="rows" width="100%"><colgroup span="1"><col align="left" valign="top" width="" span="1"/><col align="char" char="." valign="top" width="10%" span="1"/><col align="char" char="." valign="top" width="10%" span="1"/><col align="char" char="." valign="top" width="5%" span="1"/><col align="char" char="." valign="top" width="5%" span="1"/><col align="char" char="." valign="top" width="10%" span="1"/><col align="char" char="." valign="top" width="10%" span="1"/><col align="char" char="." valign="top" width="10%" span="1"/><col align="char" char="." valign="top" width="10%" span="1"/><col align="char" char="." valign="top" width="10%" span="1"/><col align="char" char="." valign="top" width="10%" span="1"/><col align="char" char="." valign="top" width="5%" span="1"/><col align="char" char="." valign="top" width="5%" span="1"/></colgroup><thead><tr><th align="center" valign="top" rowspan="2" colspan="1">Group</th><th align="center" valign="top" rowspan="2" colspan="1">Case No. (n)</th><th align="center" valign="top" colspan="5" rowspan="1">Two weeks after</th><th align="center" valign="top" colspan="5" rowspan="1">Four weeks after</th></tr><tr><th align="left" valign="top" rowspan="1" colspan="1">Physical activity</th><th align="left" valign="top" rowspan="1" colspan="1">Energy</th><th align="left" valign="top" rowspan="1" colspan="1">Sleep</th><th align="left" valign="top" rowspan="1" colspan="1">Social life</th><th align="left" valign="top" rowspan="1" colspan="1">Emotional reaction</th><th align="left" valign="top" rowspan="1" colspan="1">Physical activity</th><th align="left" valign="top" rowspan="1" colspan="1">Energy</th><th align="left" valign="top" rowspan="1" colspan="1">Sleep</th><th align="left" valign="top" rowspan="1" colspan="1">Social life</th><th align="left" valign="top" rowspan="1" colspan="1">Emotional reaction</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Treatment group</td><td align="center" rowspan="1" colspan="1">45</td><td align="left" rowspan="1" colspan="1">78.92&#x000b1;7.49</td><td align="left" rowspan="1" colspan="1">69.37&#x000b1;8.09</td><td align="left" rowspan="1" colspan="1">72.63&#x000b1;6.01</td><td align="left" rowspan="1" colspan="1">76.98&#x000b1;5.11</td><td align="left" rowspan="1" colspan="1">77.18&#x000b1;8.31</td><td align="left" rowspan="1" colspan="1">91.36&#x000b1;6.13</td><td align="left" rowspan="1" colspan="1">92.56&#x000b1;7.20</td><td align="left" rowspan="1" colspan="1">90.78&#x000b1;6.22</td><td align="left" rowspan="1" colspan="1">95.22&#x000b1;7.02</td><td align="left" rowspan="1" colspan="1">93.56&#x000b1;6.11</td></tr><tr><td align="left" rowspan="1" colspan="1">Control group</td><td align="center" rowspan="1" colspan="1">45</td><td align="left" rowspan="1" colspan="1">67.99&#x000b1;5.09</td><td align="left" rowspan="1" colspan="1">56.62&#x000b1;6.44</td><td align="left" rowspan="1" colspan="1">61.68&#x000b1;7.77</td><td align="left" rowspan="1" colspan="1">65.26&#x000b1;6.81</td><td align="left" rowspan="1" colspan="1">59.33&#x000b1;7.22</td><td align="left" rowspan="1" colspan="1">80.36&#x000b1;5.19</td><td align="left" rowspan="1" colspan="1">78.68&#x000b1;4.89</td><td align="left" rowspan="1" colspan="1">82.68&#x000b1;7.29</td><td align="left" rowspan="1" colspan="1">80.63&#x000b1;6.66</td><td align="left" rowspan="1" colspan="1">82.56&#x000b1;7.23</td></tr><tr><td align="left" rowspan="1" colspan="1">t</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">11.377</td><td align="left" rowspan="1" colspan="1">13.847</td><td align="left" rowspan="1" colspan="1">11.003</td><td align="left" rowspan="1" colspan="1">11.084</td><td align="left" rowspan="1" colspan="1">18.467</td><td align="left" rowspan="1" colspan="1">11.044</td><td align="left" rowspan="1" colspan="1">14.665</td><td align="left" rowspan="1" colspan="1">8.462</td><td align="left" rowspan="1" colspan="1">15.882</td><td align="left" rowspan="1" colspan="1">11.662</td></tr><tr><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.05</td></tr></tbody></table></table-wrap></sec></sec><sec sec-type="discussion" id="sec1-4"><title>DISCUSSION</title><p>AIDS is a chronic infectious disease caused by HIV that belongs to the genus <italic>Lentivirus</italic> of the family <italic>Retroviridae</italic> and exists in most body fluids and tissues of HIV-infected and AIDS patients. This virus is mainly transmitted by sexual contact and blood in addition to mother-to-child transmission. Upon HIV invasion, the immune system of human body is attacked and inhibited from exerting protective effects.<xref rid="ref12" ref-type="bibr">12</xref> Moreover, along with the replication of immune cell DNA, this virus is also replicated and releases more viruses to infect more cells. Finally, many types of incurable infections and tumors are generated, which lead to inevitable death owing to the lack of eligible drugs.</p><p>On the other hand, herpes zoster is related with the immune status of human body, especially with the decrease in cellular immune function. Induced by VZV [with human herpes virus 3 (HHV3) as the main pathogen], herpes zoster is clinically manifested as local nerve involvement and obvious neuralgia.<xref rid="ref13" ref-type="bibr">13</xref> During onset, this virus is activated again because of decrease in resistance or cellular immune function, which inflames involved ganglia. Notably, HIV infection remarkably increases the risk of being injected with HHV3 simultaneously.</p><p>At present, viral infection is treated by interferon in most cases mainly by fighting against virus, cell proliferation and hepatic fibrosis as well as by regulating immunity. For instance, IFN &#x003b1;-2b can directly inhibit the replication of hepatitis B virus.<xref rid="ref14" ref-type="bibr">14</xref> Besides improving immune function, interferon can also enhance macrophage phagocytosis, the killing effect of cytotoxic T cells and the function of natural killer cells. Nevertheless, interferon only has short-term effects while being dose-dependent, accompanied by possible adverse reactions as a result. Foscarnet sodium is a congener of phosphonoacetic acid, and they are both the analogues of pyrophosphates. It has previously been held that foscarnet sodium was an inhibitor of herpes simplex virus DNA polymerase, with its antiviral activities verified against cells <italic>in vitro</italic> and against guinea pigs <italic>in vivo</italic>.<xref rid="ref15" ref-type="bibr">15</xref> After four weeks, the effective rates of the treatment and control groups were 95.6% and 80.0% respectively, which were significantly different (P &#x0003c; 0.05), suggesting that foscarnet sodium effectively relieved the herpes zoster symptoms.</p><p>HIV infection complicated with herpes zoster is mainly characterized by spontaneous, needle-like, burning-like, paroxysmal pain, being different from the persistent pain caused by lumbar diseases. Hence, pain scores are usually high. When the disease occurs, patients undergo insufferable burning and itching together with neuralgia, thus being sleep-deprived in extreme cases. Approximately 14.0% of herpes zoster develops into postherpetic neuralgia as neuropathic pain that will result in severe outcomes if not treated in time. Unlike interferon that exerts only short-term effects,<xref rid="ref16" ref-type="bibr">16</xref> foscarnet sodium, which is a totally synthesized small molecule compound, functions at the pyrophosphate binding site of viral DNA polymerase. It also prevents pain sequelae by rapidly inhibiting the congestion, edema and necrosis of ganglia and corresponding sensory fibers and by preventing desmoplasia. In this study, the pain scores of the two groups were insignificantly different before treatment, but the scores of the treatment group were significantly lower than those of the control group two and four weeks after treatment (P &#x0003c; 0.05) as well as were significantly lower than those before treatment (P &#x0003c; 0.05).</p><p>Furthermore, it is well-known that CD4+ cells play an important role in maintaining immune function as the center of immune response, and HIV mainly invades human CD4+ T lymphocytes by reducing their counts and by causing functional defects. HIV infection complicated with herpes zoster can decrease CD4+ cells by hindering their maturation, and lead to indirect damages by producing autoimmune response and by inducing the apoptosis of such cells. In the meantime, Th cell-assisted or mediated immune response functions are indirectly weakened, including decrease in IL-2 production and the failure of Th cells to activate specific antigens. Acute infection is typified by plummet in the number of CD4+ T lymphocytes, which may self-recover completely or partially in most patients without special treatment. Herein, the numbers of CD4+ cells and the contents of IL-2 of both groups two and four weeks after treatment significantly exceeded those before treatment (P &#x0003c; 0.05), with significant inter-group differences also (P &#x0003c; 0.05), indicating that foscarnet sodium effectively suppressed viral infection and proliferation by regulating immune and inflammatory mechanisms. Basic and clinical studies also showed that foscarnet sodium was able to well inhibit hepatitis B virus and the activities of T, B lymphocytes.<xref rid="ref17" ref-type="bibr">17</xref> In addition, most patients tolerate foscarnet sodium well, without undergoing renal function damages if given enough water therewith.<xref rid="ref18" ref-type="bibr">18</xref> In this study, the treatment group scored significantly higher in physical activity, energy, sleep, social life and emotional reaction than the control group did two and four weeks after treatment (P &#x0003c; 0.05).</p><p>In short, HIV-infected patients are prone to being complicated with herpes zoster. Foscarnet sodium injection, compared with interferon, better improves the clinical outcomes and prognostic quality of life by effectively alleviating pain and by regulating immune mediated inflammatory diseases.</p></sec></body><back><fn-group><fn fn-type="other"><p><bold><italic>Note:</italic></bold> The first two authors contributed equally to this work.</p></fn><fn fn-type="supported-by"><p><bold><italic>Funding:</italic></bold> None.</p></fn><fn fn-type="conflict"><p><bold><italic>Conflicts of interest:</italic></bold> The authors declare no conflicts of interest.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghannad</surname><given-names>MS</given-names></name><name><surname>Solgi</surname><given-names>G</given-names></name><name><surname>Hashemi</surname><given-names>SH</given-names></name><name><surname>Zebarjady-Bagherpour</surname><given-names>J</given-names></name><name><surname>Hemmatzadeh</surname><given-names>A</given-names></name><name><surname>Hajilooi</surname><given-names>M</given-names></name></person-group><article-title>Herpes simplex virus encephalitis in hamadan, iran</article-title><source>Iran J Microbiol</source><year>2013</year><volume>5</volume><issue>3</issue><fpage>272</fpage><lpage>277</lpage><pub-id pub-id-type="pmid">24475336</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piret</surname><given-names>J</given-names></name><name><surname>Boivin</surname><given-names>G</given-names></name></person-group><article-title>Antiviral drug resistance in herpesviruses other than cytomegalovirus</article-title><source>Rev Med Virol</source><year>2014</year><volume>24</volume><issue>3</issue><fpage>186</fpage><lpage>218</lpage><comment>doi:10.1002/rmv.1787</comment><pub-id pub-id-type="pmid">24604770</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finn</surname><given-names>KM</given-names></name><name><surname>Ginns</surname><given-names>LC</given-names></name><name><surname>Robbins</surname><given-names>GK</given-names></name><name><surname>Wu</surname><given-names>CC</given-names></name><name><surname>Branda</surname><given-names>JA</given-names></name></person-group><article-title>Case records of the Massachusetts General Hospital. Case 20-2014. A 65-year-old man with dyspnea and progressively worsening lung disease</article-title><source>N Engl J Med</source><year>2014</year><volume>370</volume><issue>26</issue><fpage>2521</fpage><lpage>2530</lpage><comment>doi:10.1056/NEJMcpc1400841</comment><pub-id pub-id-type="pmid">24963572</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schaftenaar</surname><given-names>E</given-names></name><name><surname>Verjans</surname><given-names>GM</given-names></name><name><surname>Getu</surname><given-names>S</given-names></name><name><surname>McIntyre</surname><given-names>JA</given-names></name><name><surname>Struthers</surname><given-names>HE</given-names></name><name><surname>Osterhaus</surname><given-names>AD</given-names></name><etal/></person-group><article-title>High seroprevalence of human herpesviruses in HIV-infected individuals attending primary healthcare facilities in rural South Africa</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><issue>6</issue><fpage>e99243</fpage><comment>doi:10.1371/journal.pone.0099243</comment><pub-id pub-id-type="pmid">24914671</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seang</surname><given-names>S</given-names></name><name><surname>Boutolleau</surname><given-names>D</given-names></name><name><surname>Burrel</surname><given-names>S</given-names></name><name><surname>Regnier</surname><given-names>S</given-names></name><name><surname>Epelboin</surname><given-names>L</given-names></name><name><surname>Voujon</surname><given-names>D</given-names></name><etal/></person-group><article-title>Long-term follow-up of HIV-infected patients once diagnosed with acyclovir-resistant herpes simplex virus infection</article-title><source>Int J STD AIDS</source><year>2014</year><volume>25</volume><issue>9</issue><fpage>676</fpage><lpage>682</lpage><comment>doi:10.1177/0956462413518034</comment><pub-id pub-id-type="pmid">24535691</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drannik</surname><given-names>AG</given-names></name><name><surname>Nag</surname><given-names>K</given-names></name><name><surname>Sallenave</surname><given-names>JM</given-names></name><name><surname>Rosenthal</surname><given-names>KL</given-names></name></person-group><article-title>Antiviral activity of trappin-2 and elafin <italic>in vitro</italic> and <italic>in vivo</italic> against genital herpes</article-title><source>J Virol</source><year>2013</year><volume>87</volume><issue>13</issue><fpage>7526</fpage><lpage>7538</lpage><comment>doi:10.1128/JVI.02243-12</comment><pub-id pub-id-type="pmid">23637403</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leporrier</surname><given-names>J</given-names></name><name><surname>Etienne</surname><given-names>M</given-names></name><name><surname>Chapuzet</surname><given-names>C</given-names></name><name><surname>Peytavin</surname><given-names>G</given-names></name><name><surname>Bord</surname><given-names>S</given-names></name><name><surname>Borsa-Lebas</surname><given-names>F</given-names></name><etal/></person-group><article-title>Association of dolutegravir and rilpivirine, enhanced by foscarnet induction, in effective salvage antiretroviral therapy</article-title><source>Clin Virol</source><year>2014</year><volume>60</volume><issue>4</issue><fpage>428</fpage><lpage>430</lpage><comment>doi:10.1016/j.jcv.2014.05.004</comment></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Be&#x00148;ov&#x000e1;</surname><given-names>A</given-names></name><name><surname>Brichov&#x000e1;</surname><given-names>M</given-names></name><name><surname>Svoz&#x000ed;lkov&#x000e1;</surname><given-names>P</given-names></name><name><surname>Kousal</surname><given-names>B</given-names></name><name><surname>Jen&#x000ed;&#x0010d;kov&#x000e1;</surname><given-names>D</given-names></name><name><surname>Heissigerov&#x000e1;</surname><given-names>J</given-names></name><etal/></person-group><article-title>Cytomegalovirus retinitis in HIV negative patients - retrospective study</article-title><source>Cesk Slov Oftalmol</source><year>2013</year><volume>69</volume><issue>6</issue><fpage>227</fpage><lpage>234</lpage><pub-id pub-id-type="pmid">24697533</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>JB</given-names></name><name><surname>Shaw</surname><given-names>FE</given-names></name></person-group><article-title>Relationship of income and health care coverage to receipt of recommended clinical preventive services by adults - United States, 2011-2012</article-title><source>MMWR Morb Mortal Wkly Rep</source><year>2014</year><volume>63</volume><issue>31</issue><fpage>666</fpage><lpage>670</lpage><pub-id pub-id-type="pmid">25102414</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shahapur</surname><given-names>PR</given-names></name><name><surname>Bidri</surname><given-names>RC</given-names></name></person-group><article-title>Recent trends in the spectrum of opportunistic infections in human immunodeficiency virus infected individuals on antiretroviral therapy in South India</article-title><source>J Nat Sci Biol Med</source><year>2014</year><volume>5</volume><issue>2</issue><fpage>392</fpage><lpage>396</lpage><comment>doi:10.4103/0976-9668.136200</comment><pub-id pub-id-type="pmid">25097422</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Todesco</surname><given-names>E</given-names></name><name><surname>Sayon</surname><given-names>S</given-names></name><name><surname>Fourati</surname><given-names>S</given-names></name><name><surname>Tubiana</surname><given-names>R</given-names></name><name><surname>Simon</surname><given-names>A</given-names></name><name><surname>Ktorza</surname><given-names>N</given-names></name><etal/></person-group><article-title>Highly multidrug-resistant HIV: clonal analysis and therapeutic strategies</article-title><source>J Antimicrob Chemother</source><year>2013</year><volume>68</volume><issue>12</issue><fpage>2882</fpage><lpage>2889</lpage><comment>doi:10.1093/jac/dkt272</comment><pub-id pub-id-type="pmid">23873645</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ehteshami</surname><given-names>M</given-names></name><name><surname>Nijhuis</surname><given-names>M</given-names></name><name><surname>Bernatchez</surname><given-names>JA</given-names></name><name><surname>Ablenas</surname><given-names>CJ</given-names></name><name><surname>McCormick</surname><given-names>S</given-names></name><name><surname>de Jong</surname><given-names>D</given-names></name><etal/></person-group><article-title>Formation of a quaternary complex of HIV-1 reverse transcriptase with a nucleotide-competing inhibitor and its ATP enhancer</article-title><source>J Biol Chem</source><year>2013</year><volume>288</volume><issue>24</issue><fpage>17336</fpage><lpage>17346</lpage><comment>doi:10.1074/jbc.M112.433441</comment><pub-id pub-id-type="pmid">23598281</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>MR</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Atianand</surname><given-names>M</given-names></name><name><surname>Jensen</surname><given-names>SB</given-names></name><name><surname>Carpenter</surname><given-names>S</given-names></name><name><surname>Knipe</surname><given-names>DM</given-names></name><etal/></person-group><article-title>Interferon &#x003b3;-inducible Protein (IFI) 16 Transcriptionally Regulates Type I Interferons and Other Interferon-stimulated Genes and Controls the Interferon Response to both DNA and RNA Viruses</article-title><source>J Biol Chem</source><year>2014</year><volume>89</volume><issue>34</issue><fpage>23568</fpage><lpage>23581</lpage><comment>doi:10.1074/jbc.M114.554147</comment><pub-id pub-id-type="pmid">25002588</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herold</surname><given-names>BC</given-names></name><name><surname>Dezzutti</surname><given-names>CS</given-names></name><name><surname>Richardson</surname><given-names>BA</given-names></name><name><surname>Marrazzo</surname><given-names>J</given-names></name><name><surname>Mesquita</surname><given-names>PM</given-names></name><name><surname>Carpenter</surname><given-names>C</given-names></name><etal/></person-group><article-title>Antiviral activity of genital tract secretions after oral or topical tenofovir pre-exposure prophylaxis for HIV-1</article-title><source>J Acquir Immune Defic Syndr</source><year>2014</year><volume>66</volume><issue>1</issue><fpage>65</fpage><lpage>73</lpage><comment>doi:10.1097/QAI.0000000000000110</comment><pub-id pub-id-type="pmid">24457633</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nixon</surname><given-names>B</given-names></name><name><surname>Fakioglu</surname><given-names>E</given-names></name><name><surname>Stefanidou</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Dutta</surname><given-names>M</given-names></name><name><surname>Goldstein</surname><given-names>H</given-names></name><etal/></person-group><article-title>Genital herpes simplex virus type 2 infection in humanized HIV-transgenic mice triggers HIV shedding and is associated with greater neurological disease</article-title><source>J Infect Dis</source><year>2014</year><volume>209</volume><issue>4</issue><fpage>510</fpage><lpage>522</lpage><comment>doi:10.1093/infdis/jit472</comment><pub-id pub-id-type="pmid">23990571</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akinboro</surname><given-names>AO</given-names></name><name><surname>Onayemi</surname><given-names>O</given-names></name><name><surname>Mejiuni</surname><given-names>AD</given-names></name></person-group><article-title>Frequency, pattern, and extent of skin diseases in relation to CD4+cell count among adults with human immunodeficiency virus infection or acquired immunodeficiency syndrome in Osogbo, southwestern Nigeria</article-title><source>Int J Dermatol</source><year>2014</year><volume>53</volume><issue>4</issue><fpage>416</fpage><lpage>424</lpage><comment>doi:10.1111/j.1365-4632.2012.05820.x</comment><pub-id pub-id-type="pmid">24783258</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siddiqi</surname><given-names>OK</given-names></name><name><surname>Ghebremichael</surname><given-names>M</given-names></name><name><surname>Dang</surname><given-names>X</given-names></name><name><surname>Atadzhanov</surname><given-names>M</given-names></name><name><surname>Kaonga</surname><given-names>P</given-names></name><name><surname>Khoury</surname><given-names>MN</given-names></name><etal/></person-group><article-title>Molecular diagnosis of central nervous system opportunistic infections in HIV-infected Zambian adults</article-title><source>Clin Infect Dis</source><year>2014</year><volume>58</volume><issue>12</issue><fpage>1771</fpage><lpage>1777</lpage><comment>doi:10.1093/cid/ciu191</comment><pub-id pub-id-type="pmid">24668125</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aissani</surname><given-names>B</given-names></name><name><surname>Wiener</surname><given-names>HW</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Kaslow</surname><given-names>RA</given-names></name><name><surname>Ogwaro</surname><given-names>KM</given-names></name><name><surname>Shrestha</surname><given-names>S</given-names></name><etal/></person-group><article-title>A candidate gene approach for virally induced cancer with application to HIV-related Kaposi's sarcoma</article-title><source>Int J Cancer</source><year>2014</year><volume>134</volume><issue>2</issue><fpage>397</fpage><lpage>404</lpage><comment>doi:10.1002/ijc.28351</comment><pub-id pub-id-type="pmid">23818101</pub-id></element-citation></ref></ref-list><sec id="sec2-17"><title>Authors&#x02019; Contribution</title><p><bold>YYQ&#x00026;XMP:</bold> Conceived, designed and did statistical analysis &#x00026; editing of manuscript.</p><p><bold>XJK &#x00026; CXA:</bold> Did data collection and manuscript writing.</p><p><bold>XMP:</bold> Did review and gave final approval of manuscript.</p><p><bold>XMP:</bold> Takes the responsibility and is accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.</p></sec></back></article>